6CM
SGMT icon

683 Capital Management’s Sagimet Biosciences SGMT Stock Holding History

683 Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Hold
126,349
– – 0.03% 163
2025
Q4 		$748K Buy
+126,349
New +$908K 0.03% 166
2025
Q1 		– Sell
-138,263
Closed -$622K – 226
2024
Q4 		$622K Buy
+138,263
New +$700K 0.04% 143

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

683 Capital Management's SGMT Position: Q1 2026 in Review

683 Capital Management held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 126,349 shares worth $660K. The position accounts for 0.03% of the portfolio, ranked #163.

683 Capital Management first reported a position in SGMT in Q4 2024 and has held it in 3 quarters since. The position peaked at $748K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • 683 Capital Management held 126,349 shares of Sagimet Biosciences worth $660K as of Q1 2026.
  • 683 Capital Management left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up 0.03% of 683 Capital Management's portfolio in Q1 2026, its #163 holding.
  • 683 Capital Management first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 683 Capital Management's Sagimet Biosciences position peaked at $748K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.